Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 50 citing articles:

Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials
Faraidoon Haghdoost, Francesca Puledda, David García‐Azorín, et al.
Cephalalgia (2023) Vol. 43, Iss. 4
Open Access | Times Cited: 78
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis
Roberta Messina, Eva‐Maria Huessler, Francesca Puledda, et al.
Cephalalgia (2023) Vol. 43, Iss. 3
Open Access | Times Cited: 76
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 65
From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment
Masaru Tanaka, Ágnes Szabó, Tamás Körtési, et al.
Cells (2023) Vol. 12, Iss. 22, pp. 2649-2649
Open Access | Times Cited: 40
Future targets for migraine treatment beyond CGRP
Linda Al‐Hassany, Deirdre M. Boucherie, Hannah Creeney, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 29
Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis
Seyran Naghdi, Martin Underwood, Jason Madan, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 21
Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
Calcitonin gene‐related peptide (CGRP) is a key molecule released in acute migraine attacks—Successful translation of basic science to clinical practice
Lars Edvinsson
Journal of Internal Medicine (2022) Vol. 292, Iss. 4, pp. 575-586
Open Access | Times Cited: 23
An observational study on monoclonal antibodies against calcitonin‐gene‐related peptide and its receptor
Francesca Schiano di Cola, Marco Bolchini, Giulia Ceccardi, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 6, pp. 1764-1773
Open Access | Times Cited: 16
Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans
Thien Phu, Christina Deligianni, Sarkhan Amirguliyev, et al.
Brain (2023) Vol. 146, Iss. 12, pp. 5224-5234
Open Access | Times Cited: 16
A head‐to‐head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene–related peptide for chronic and episodic migraine
Francesco Saccà, Simone Braca, Mattia Sansone, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 63, Iss. 6, pp. 788-794
Open Access | Times Cited: 11
New Approaches to Shifting the Migraine Treatment Paradigm
Brian F. G. Johnson, Frederick G. Freitag
Frontiers in Pain Research (2022) Vol. 3
Open Access | Times Cited: 18
Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
Andreas A. Argyriou, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3218-3218
Open Access | Times Cited: 10
Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine
Andrea Lovato, Caterina Disco, Andrea Frosolini, et al.
Medicina (2023) Vol. 59, Iss. 9, pp. 1560-1560
Open Access | Times Cited: 10
Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review
Seyran Naghdi, Martin Underwood, Anna Brown, et al.
BMJ Neurology Open (2024) Vol. 6, Iss. 1, pp. e000616-e000616
Open Access | Times Cited: 3
Predictors of Response to Treatment With Anti-calcitonin Gene-Related Peptide (CGRP) Antibodies in Real-World Patients With Episodic Migraine: A Two- and Four-Month Prospective Study
Abouch Valenty Krymchantowski, Carla Jevoux, Raimundo Pereira Silva‐Néto, et al.
Cureus (2025)
Open Access
Efficacy and tolerability of the ketogenic diet and its variations for preventing migraine in adolescents and adults: a systematic review
Madson C Caminha, Adriana Boschi Moreira, Filipe C. Matheus, et al.
Nutrition Reviews (2021) Vol. 80, Iss. 6, pp. 1634-1647
Closed Access | Times Cited: 22
Effects of Fremanezumab on Psychiatric Comorbidities in Difficult-to-Treat Patients with Chronic Migraine: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
Michail Vikelis, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4526-4526
Open Access | Times Cited: 9
Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review
Meghana Reddy Muddam, Omobolanle A Obajeun, Abdelrahman Abaza, et al.
Cureus (2023)
Open Access | Times Cited: 7
Management of Chronic Migraine in Children and Adolescents: Where are We in 2022?
Robert C. Gibler, Kaelynn E. Knestrick, Brooke L. Reidy, et al.
Pediatric Health Medicine and Therapeutics (2022) Vol. Volume 13, pp. 309-323
Open Access | Times Cited: 12
Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling
Hema Mistry, Seyran Naghdi, Anna Brown, et al.
Health Technology Assessment (2024), pp. 1-329
Open Access | Times Cited: 2
Higher Circulating Vitamin D Levels Are Associated With Decreased Migraine Risk: A Mendelian Randomization Study
Peng‐Peng Niu, Xue Wang, Yuming Xu
Frontiers in Nutrition (2022) Vol. 9
Open Access | Times Cited: 10
Characteristics associated with response to subcutaneously administered anti‐CGRP monoclonal antibody medications in a real‐world community cohort of persons living with migraine: A retrospective clinical and genetic study
Bruce A. Chase, Irene Semenov, Susan Rubin, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 64, Iss. 1, pp. 68-92
Open Access | Times Cited: 6
Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society
Katina Aleksovska, Andrew D. Hershey, Marie Deen, et al.
Cephalalgia (2023) Vol. 43, Iss. 10
Open Access | Times Cited: 4
Documento de consenso de la Sociedad Española de Neurología (SEN), Sociedad Española de Medicina de Familia y Comunitaria (SEMFYC), Sociedad de Medicina de Atención Primaria (SEMERGEN) y Asociación Española de Migraña y Cefalea (AEMICE) sobre el tratamiento de la migraña
R. Belvís, Pablo Irimia, Nuria González, et al.
Medicina Clínica (2024) Vol. 163, Iss. 4, pp. 208.e1-208.e10
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top